

Claims:

1. A pharmaceutical composition for topical administration, comprising a phthalocyanine photosensitizer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 2. A pharmaceutical composition of claim 1, wherein the phthalocyanine has a structure of formula (I) or a pharmaceutically acceptable salt thereof




(I)

10 wherein Pc is a substituted or unsubstituted phthalocyanine; and

M is a diamagnetic metal ion, optionally complexed with or covalently bound to one or two axial ligands, wherein the metal ion is coordinated to the phthalocyanine moiety.

15 3. A pharmaceutical composition of claim 1, wherein the phthalocyanine has a structure of formula (II) or a pharmaceutically acceptable salt thereof




(II)

20 wherein M is a diamagnetic metal ion optionally complexed with or covalently bound to one or two axial ligands, wherein the metal ion is coordinated to the phthalocyanine moiety; and

- $R^1 - R^{16}$ are each independently selected from hydrogen, halogen, nitro, cyano, hydroxy, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C_{1-20} alkyl, C_{1-20} alkenyl, C_{1-20} alkynyl, C_{1-20} alkoxy, C_{1-20} acyl, C_{1-20} alkylcarbonyloxy, C_{1-20} aralkyl, C_{1-20} heteraralkyl, C_{1-20} carbocyclalkyl, C_{1-20} heterocyclalkyl, C_{1-20} aminoalkyl, C_{1-20} alkylamino, C_{1-20} thioalkyl, C_{1-20} alkylthio, C_{1-20} hydroxyalkyl, C_{1-20} alkyloxycarbonyl, C_{1-20} alkylaminocarbonyl, C_{1-20} alkylcarbonylamino, C_{1-10} alkyl-Z- C_{1-10} alkyl;
- R^{17} is selected from hydrogen, C_{1-20} acyl, C_{1-20} alkyl, and C_{1-20} aralkyl; and
- Z is selected from S, NR^{17} , and O.

4. A pharmaceutical composition of claim 1, wherein the phthalocyanine has a structure of Formula (III) or a pharmaceutically acceptable salt thereof



(III)


- wherein M is $(G)_a Y[(OSi(CH_3)_2(CH_2)_b N_c(R')_d(R'')_e)_f X_g]_p$;
- Y is selected from Si, Al, Ga, Ge, or Sn;
- R' is selected from H, CH_3 , C_2H_5 , C_4H_9 , C_4H_8NH , C_4H_8N , $C_4H_8NCH_3$, C_4H_8S , C_4H_8O , C_4H_8Se , $OC(O)CH_3$, $OC(O)$, CS, CO, CSe, OH, $C_4H_8N(CH_2)_3CH_3$, $(CH_2)_2N(CH_3)_2$, $(CH_2)_nN((CH_2)_o(CH_3))_2$, and an alkyl group having from 1 to 12 carbon atoms;
- R'' is selected from H, SO_2CH_3 , $(CH_2)_2N(CH_3)_2$, $(CH_2)_{11}CH_3$, $C(S)NHC_6H_{11}O_5$, $(CH_2)_nN((CH_2)_o(CH_3))_2$, and an alkyl group having from 1 to 12 carbon atoms;
- G is selected from OH and CH_3 ;

- X is selected from I, F, Cl, or Br;
- a is 0 or 1;
- b is an integer from 2 to 12;
- c is 0 or 1;
- 5 d is an integer from 0 to 3;
- e is an integer from 0 to 2;
- f is 1 or 2;
- g is 0 or 1;
- n is an integer from 1 to 12;
- 10 o is an integer from 1 to 11; and
- p is 1 or 2.

5. A pharmaceutical composition of claim 4, wherein M is selected from $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$; $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$; $\text{CH}_3\text{SiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
- 15 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_4\text{NH}_2]_2$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_4\text{NHSO}_2\text{CH}_3]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_4\text{NHSO}_2\text{CH}_3$;
- $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_3)(\text{CH}_2)_2\text{N}(\text{CH}_3)_2$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_4\text{NHCSNHC}_6\text{H}_{11}\text{O}_5]_2$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$;
- 20 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{OCOCH}_3$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{OH}$;
- $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_3)(\text{CH}_2)_2\text{N}(\text{CH}_3)_2]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{O}$;
- $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}^+(\text{CH}_3)_2(\text{CH}_2)_{11}\text{CH}_3\text{I}^-$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_8\text{N}(\text{CH}_3)_2$;
- $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{O}]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{S}$;
- $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_2)_3(\text{CH}_3)_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NCS}$;
- 25 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}[(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{NCH}_3$;
- $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{NCH}_3]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{N}(\text{CH}_2)_3\text{CH}_3$; and $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{NH}]_2$.

6. A pharmaceutical composition of claim 5, wherein M is
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$.

7. A pharmaceutical composition of claim 1, wherein the
 phthalocyanine has a structure of Formula (IV) or a pharmaceutically acceptable salt
 5 thereof



(IV)

wherein R^1 is selected from H and R^2 ;

each R^2 is independently $\text{Si}(\text{R}^3)_2(\text{C}_{1-12}\text{alkyl}-\text{N}(\text{C}_{1-12}\text{alkyl})_2)$;

10 each R^3 is independently selected from $\text{C}_{1-12}\text{alkyl}$, $\text{C}_{1-12}\text{alkoxy}$, $\text{C}_{1-12}\text{aralkyl}$, aryloxy,
 and aryl.

8. A pharmaceutical composition of any one of claims 1-7, wherein the
 phthalocyanine is formulated as a salt selected from hydrobromide, hydrochloride,
 sulfate, bisulfate, phosphate, nitrate, acetate, pyruvate, valerate, oleate, palmitate,
 15 stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate,
 succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and
 laurylsulphonate salts.

9. A pharmaceutical composition of claim 8, wherein the
 phthalocyanine is formulated as a salt selected from hydrochloride and pyruvate.

20 10. A pharmaceutical composition of claim 9, wherein the
 phthalocyanine is formulated as a hydrochloride salt.

11. A pharmaceutical composition of claim 10, wherein the
 phthalocyanine is formulated as a pyruvate salt.

12. A method for treating epithelial cancer, comprising
 25 (i) topically administering a photosensitizer to an epithelial surface; and

(ii) irradiating the epithelial surface.

13. A method of claim 12, further comprising a pharmaceutically acceptable carrier.

14. A method of claim 13, wherein the photosensitizer is a phthalocyanine or a pharmaceutically acceptable salt thereof.


15. A method of claim 14, wherein the phthalocyanine has a structure of formula (I) or a pharmaceutically acceptable salt thereof



(I)

10 wherein Pc is a substituted or unsubstituted phthalocyanine; and
M is a diamagnetic metal ion, optionally complexed with or covalently bound to one or two axial ligands, wherein the metal ion is coordinated to the phthalocyanine moiety.

16. A pharmaceutical composition of claim 14, wherein the phthalocyanine has a structure of formula (II) or a pharmaceutically acceptable salt thereof




(II)

wherein M is a diamagnetic metal ion optionally complexed with or covalently bound to one or two axial ligands, wherein the metal ion is coordinated to the phthalocyanine moiety; and

- 5 $R^1 - R^{16}$ are each independently selected from hydrogen, halogen, nitro, cyano, hydroxy, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C_{1-20} alkyl, C_{1-20} alkenyl, C_{1-20} alkynyl, C_{1-20} alkoxy, C_{1-20} acyl, C_{1-20} alkylcarbonyloxy, C_{1-20} aralkyl, C_{1-20} heteralkyl, C_{1-20} carbocyclalkyl, C_{1-20} heterocyclalkyl, C_{1-20} aminoalkyl, C_{1-20} alkylamino, C_{1-20} thioalkyl, C_{1-20} alkylthio, C_{1-20} hydroxyalkyl, C_{1-20} alkyloxycarbonyl, C_{1-20} alkylaminocarbonyl, C_{1-20} alkylcarbonylamino, C_{1-10} alkyl-Z- C_{1-10} alkyl;
- 10 R^{17} is selected from hydrogen, C_{1-20} acyl, C_{1-20} alkyl, and C_{1-20} aralkyl; and Z is selected from S, NR^{17} , and O.

17. A method of claim 14, wherein the phthalocyanine has a structure of Formula (III) or a pharmaceutically acceptable salt thereof



(III)

15

wherein M is $(G)_a Y[(OSi(CH_3)_2(CH_2)_b N_c(R')_d(R'')_e)X_g]_p$;

Y is selected from Si, Al, Ga, Ge, or Sn;

- 20 R' is selected from H, CH_3 , C_2H_5 , C_4H_9 , C_4H_8NH , C_4H_8N , $C_4H_8NCH_3$, C_4H_8S , C_4H_8O , C_4H_8Se , $OC(O)CH_3$, $OC(O)$, CS, CO, CSe, OH, $C_4H_8N(CH_2)_3CH_3$, $(CH_2)_2N(CH_3)_2$, $(CH_2)_nN((CH_2)_o(CH_3))_2$, and an alkyl group having from 1 to 12 carbon atoms;;

R" is selected from H, SO₂CH₃, (CH₂)₂N(CH₃)₂, (CH₂)₁₁CH₃, C(S)NHC₆H₁₁O₅,
(CH₂)_nN((CH₂)_o(CH₃))₂, and an alkyl group having from 1 to 12 carbon
atoms;

G is selected from OH and CH₃;

5 X is selected from I, F, Cl, or Br;

a is 0 or 1;

b is an integer from 2 to 12;

c is 0 or 1;

d is an integer from 0 to 3;

10 e is an integer from 0 to 2;

f is 1 or 2;

g is 0 or 1;

n is an integer from 1 to 12;

o is an integer from 1 to 11; and

15 p is 1 or 2.

18. A method of claim 17, wherein M is selected from

AlOSi(CH₃)₂(CH₂)₃N(CH₃)₂; AlOSi(CH₃)₂(CH₂)₃N(CH₃)₃⁺T⁻;

CH₃SiOSi(CH₃)₂(CH₂)₃N(CH₃)₂; HOSiOSi(CH₃)₂(CH₂)₃N(CH₃)₂;

HOSiOSi(CH₃)₂(CH₂)₃N(CH₃)₃⁺T⁻; Si[OSi(CH₃)₂(CH₂)₃N(CH₃)₃⁺T⁻]₂;

20 Si[OSi(CH₃)₂(CH₂)₄NH₂]₂; Si[OSi(CH₃)₂(CH₂)₄NHSO₂CH₃]₂;

HOSiOSi(CH₃)₂(CH₂)₄NHSO₂CH₃;

HOSiOSi(CH₃)₂(CH₂)₃N(CH₂CH₃)(CH₂)₂N(CH₃)₂; Si[OSi(CH₃)₂(CH₂)₄

NHCSNHC₆H₁₁O₅]₂; Si[OSi(CH₃)₂(CH₂)₃N(CH₃)₂]₂;

HOSiOSi(CH₃)₂(CH₂)₃OCOCH₃; HOSiOSi(CH₃)₂(CH₂)₃OH;

25 Si[OSi(CH₃)₂(CH₂)₃N(CH₂CH₃)(CH₂)₂N(CH₃)₂]₂; HOSiOSi(CH₃)₂(CH₂)₃NC₄H₈O;

AlOSi(CH₃)₂(CH₂)₃N⁺(CH₃)₂(CH₂)₁₁CH₃I⁻; HOSiOSi(CH₃)₂(CH₂)₈N(CH₃)₂;

Si[OSi(CH₃)₂(CH₂)₃NC₄H₈O]₂; HOSiOSi(CH₃)₂(CH₂)₃NC₄H₈S;

HOSiOSi(CH₃)₂(CH₂)₃N(CH₂)₃(CH₃)₂; HOSiOSi(CH₃)₂(CH₂)₃NCS;

HOSiOSi(CH₃)₂(CH₂)₃N[(CH₂)₃N(CH₃)₂]₂; HOSiOSi(CH₃)₂(CH₂)₃NC₄H₈NCH₃; Si[OSi(CH₃)₂(CH₂)₃NC₄H₈NCH₃]₂; HOSiOSi(CH₃)₂(CH₂)₃NC₄H₈N(CH₂)₃CH₃; and Si[OSi(CH₃)₂(CH₂)₃NC₄H₈NH]₂.

19. A method of claim 18, wherein M is HOSiOSi(CH₃)₂(CH₂)₃N(CH₃)₂.

5 20. A method of claim 14, wherein the phthalocyanine has a structure of Formula (IV) or a pharmaceutically acceptable salt thereof



(IV)

wherein R¹ is selected from H and R²;

10 each R² is independently Si(R³)₂(C₁₋₁₂alkyl-N(C₁₋₁₂alkyl)₂);

each R³ is independently selected from C₁₋₁₂alkyl, C₁₋₁₂alkoxy, C₁₋₁₂aralkyl, aryloxy, and aryl.

21. A method of claim 12, wherein the phthalocyanine is formulated as a salt selected from hydrobromide, hydrochloride, sulfate, bisulfate, phosphate,
15 nitrate, acetate, pyruvate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts.

22. A method of any one of claims 15-20, wherein the phthalocyanine is formulated as a salt selected from hydrochloride and pyruvate.

20 23. A pharmaceutical composition of claim 22, wherein the phthalocyanine is formulated as a hydrochloride salt.

24. A method of claim 22, wherein the phthalocyanine is formulated as a pyruvate salt.

25 25. A pharmaceutically acceptable salt of a compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof




(I)

wherein Pc is a substituted or unsubstituted phthalocyanine; and

M is a diamagnetic metal ion, optionally complexed with or covalently bound to one
 5 or two axial ligands, wherein the metal ion is coordinated to the
 phthalocyanine moiety.

26. A pharmaceutically acceptable salt of a compound having a structure
 of formula (II) or a pharmaceutically acceptable salt thereof



(II)


wherein M is a diamagnetic metal ion optionally complexed with or covalently
 bound to one or two axial ligands, wherein the metal ion is coordinated to the
 phthalocyanine moiety; and

$R^1 - R^{16}$ are each independently selected from hydrogen, halogen, nitro, cyano,
 15 hydroxy, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl,
 C_{1-20} alkyl, C_{1-20} alkenyl, C_{1-20} alkynyl, C_{1-20} alkoxy, C_{1-20} acyl, C_{1-20}
 alkylcarbonyloxy, C_{1-20} aralkyl, C_{1-20} hetaralkyl, C_{1-20} carbocyclylalkyl, C_{1-20}
 heterocyclylalkyl, C_{1-20} aminoalkyl, C_{1-20} alkylamino, C_{1-20} thioalkyl, C_{1-20}
 alkylthio, C_{1-20} hydroxyalkyl, C_{1-20} alkyloxycarbonyl, C_{1-20}
 20 alkylaminocarbonyl, C_{1-20} alkylcarbonylamino, C_{1-10} alkyl-Z- C_{1-10} alkyl;

R^{17} is selected from hydrogen, C_{1-20} acyl, C_{1-20} alkyl, and C_{1-20} aralkyl; and

Z is selected from S, NR^{17} , and O.

27. A pharmaceutically acceptable salt of a compound having a structure of Formula (III) or a pharmaceutically acceptable salt thereof



(III)

- 5 wherein M is $(G)_a Y[(OSi(CH_3)_2(CH_2)_b N_c(R')_d(R'')_e)X_g]_p$;
 Y is selected from Si, Al, Ga, Ge, or Sn;
 R' is selected from H, CH₃, C₂H₅, C₄H₉, C₄H₈NH, C₄H₈N, C₄H₈NCH₃, C₄H₈S,
 C₄H₈O, C₄H₈Se, OC(O)CH₃, OC(O), CS, CO, CSe, OH, C₄H₈N(CH₂)₃CH₃,
 (CH₂)₂N(CH₃)₂, (CH₂)_nN((CH₂)₆(CH₃))₂, and an alkyl group having from 1
 10 to 12 carbon atoms;;
 R'' is selected from H, SO₂CH₃, (CH₂)₂N(CH₃)₂, (CH₂)₁₁CH₃, C(S)NHC₆H₁₁O₅,
 (CH₂)_nN((CH₂)₆(CH₃))₂, and an alkyl group having from 1 to 12 carbon
 atoms;
 G is selected from OH and CH₃;
 15 X is selected from I, F, Cl, or Br;
 a is 0 or 1;
 b is an integer from 2 to 12;
 c is 0 or 1;
 d is an integer from 0 to 3;
 20 e is an integer from 0 to 2;
 f is 1 or 2;
 g is 0 or 1;
 n is an integer from 1 to 12;

o is an integer from 1 to 11; and

p is 1 or 2.

28. A pharmaceutically acceptable salt of claim 17, wherein M is selected from $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$; $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{T}^-$;
 5 $\text{CH}_3\text{SiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{T}^-$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{T}^-]_2$;
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_4\text{NH}_2]_2$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_4\text{NHSO}_2\text{CH}_3]_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_4\text{NHSO}_2\text{CH}_3$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_3)(\text{CH}_2)_2\text{N}(\text{CH}_3)_2$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_4$
 10 $\text{NHCSNHC}_6\text{H}_{11}\text{O}_5]_2$; $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{OCOCH}_3$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{OH}$;
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_3)(\text{CH}_2)_2\text{N}(\text{CH}_3)_2]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{O}$;
 $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}^+(\text{CH}_3)_2(\text{CH}_2)_{11}\text{CH}_3\text{I}^-$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_8\text{N}(\text{CH}_3)_2$;
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{O}]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{S}$;
 15 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_2)_3(\text{CH}_3)_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NCS}$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}[(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{NCH}_3$;
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{NCH}_3]_2$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{N}(\text{CH}_2)_3\text{CH}_3$; and
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{NC}_4\text{H}_8\text{NH}]_2$.

29. A pharmaceutically acceptable salt of claim 18, wherein M is
 20 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$.

30. A pharmaceutically acceptable salt of claim 14, wherein the phthalocyanine has a structure of Formula (IV) or a pharmaceutically acceptable salt thereof



25 (IV)

wherein R^1 is selected from H and R^2 ;

each R^2 is independently $\text{Si}(\text{R}^3)_2(\text{C}_{1-12}\text{alkyl}-\text{N}(\text{C}_{1-12}\text{alkyl})_2)$;

each R³ is independently selected from C₁₋₁₂alkyl, C₁₋₁₂alkoxy, C₁₋₁₂aralkyl, aryloxy, and aryl.

31. A salt of any one of claims 25-30, wherein the salt is the hydrochloric salt.

5 32. A salt of any one of claims 25-30, wherein the salt is the pyruvate salt.

33. A pharmaceutical composition comprising a salt any one of claims 25-30 and a pharmaceutically acceptable carrier.